We scan new podcasts and send you the top 5 insights daily.
ProMIS reported six-month blinded interim data with zero ARIA-E, background ARIA-H similar to placebo, and declines in p-tau217 and MTBR243. Warma stresses they did not look at clinical outcomes, so the unblinded Q1 read is still needed to show actual benefit. He says the interim met or overachieved expectations on safety and target engagement.
Decisions to delay reporting positive interim results, as seen in LITESPARK 011 and other major trials, are often driven by the Independent Data Monitoring Committee (IDMC), not investigators. This highlights the IDMC's power in managing trial conduct, especially when co-primary endpoints like Overall Survival are immature and require longer follow-up.
Instead of stopping a trial early for success—which regulators may restrict—a high-confidence early signal provides immense value as business intelligence. This allows sponsors to de-risk and accelerate planning for subsequent phases months earlier, creating millions in value by reducing the gap between Phase 2 and 3.
Biogen is proceeding to a Phase 3 trial with its tau-targeting Alzheimer's drug even though the mid-stage study technically failed its primary endpoint. The lowest dose performed best, contrary to expectations. This signals a strategy of pushing forward with mechanistically promising but complex drugs by positively framing ambiguous data.
Warma says ProMIS chose a 140-patient, 12-month phase 1b instead of a quick 30-patient biomarker study. By checking safety, target engagement, dose, and clinical signal, they hope to move straight into a registration phase 3, saving years and cost. He says the longer, costlier design was deliberate because short biomarker studies left partners unsure.
Biogen is proceeding with its anti-tau therapy Duranderson, even though it missed its primary endpoint. The rationale is that the observed slowing of cognitive decline on secondary measures (26-50%) is comparable, or even slightly better than, the results of already-approved anti-amyloid antibodies. This strategy shows how a technically 'failed' trial can find a path forward by meeting the efficacy bar set by existing treatments.
Warma says when ProMIS proposed the larger phase 1b, investors were more interested than in a quick-and-dirty study because they saw the path to skipping phase 2. Pharma partners also responded well to the comprehensive design. He notes the tradeoff is a longer public-company news wait and higher cost, but the pros outweighed cons.
Despite their potential to save time and money, a large majority of commercial Phase 2 and 3 clinical trials in 2023 did not include a pre-planned interim analysis. This indicates a massive, underutilized opportunity to identify failing drugs sooner and reallocate resources more effectively.
The FDA's focus on one-year data is flawed because the biological mechanism of some gene therapies requires a long ramp-up period. The therapy is essentially building an 'mRNA factory' in the brain, and it takes time for this to translate into measurable clinical benefits, which become more robust in years two and three.
Interpreting early-stage, open-label epilepsy trial data requires nuance. A high seizure reduction percentage confirms a drug is likely effective, but investors should expect a significant drop in that effect size in a placebo-controlled study. The key takeaway is mechanistic validation, not the specific number.
Warma says drugs can completely eliminate plaque while patients continue to decline, and plaque-binding drugs carry ARIA risk. He argues the industry now sees toxic oligomers as the subspecies driving cognitive decline, making plaque a less relevant or insufficient target. That shift explains why ProMIS is not chasing plaque clearance as its main endpoint.